These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26813592)

  • 1. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma.
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Cui D; Li L; Zhang Y; Mu X; Zhang L; Yang L; Di J; Yu Q; Liu D
    Per Med; 2015 Aug; 12(4):349-357. PubMed ID: 29771657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
    J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of conventional smears and liquid-based cytologic slides of lymphatic metastasis specimens of lung adenocarcinoma acquired by fine needle aspiration to detect the expression of anaplastic lymphoma kinase protein].
    Jia J; Zhao LL; Guo HQ; Zhao H; Zhang ZH; Guo L; Ying JM
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):422-427. PubMed ID: 29936767
    [No Abstract]   [Full Text] [Related]  

  • 10. [ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma].
    Liang X; Wang M; Zhang J; Luo Y; Zhang S; Wu S; Liu Y; Zeng X
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):501-4. PubMed ID: 25327654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wang Z; Wu X; Han X; Cheng G; Mu X; Zhang Y; Cui D; Liu C; Liu D; Shi Y
    Chin J Cancer Res; 2016 Dec; 28(6):606-616. PubMed ID: 28174489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
    Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
    Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
    J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.